Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) CFO David Barter sold 12,134 shares of the firm’s stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $11.21, for a total transaction of $136,022.14. Following the transaction, the chief financial officer owned 322,085 shares of the company’s stock, valued at approximately $3,610,572.85. This represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Cellebrite DI Trading Up 1.1%
NASDAQ CLBT opened at $11.50 on Thursday. Cellebrite DI Ltd. has a 1-year low of $9.58 and a 1-year high of $19.98. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of 52.28, a PEG ratio of 1.74 and a beta of 1.14. The stock’s 50 day moving average is $11.36 and its two-hundred day moving average is $13.04.
Analyst Ratings Changes
CLBT has been the subject of several analyst reports. Lake Street Capital cut their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. DA Davidson reaffirmed a “buy” rating and issued a $15.00 price target on shares of Cellebrite DI in a research note on Tuesday, September 15th. Weiss Ratings cut Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. Needham & Company LLC dropped their price objective on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, JPMorgan Chase & Co. dropped their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and an average target price of $16.70.
Check Out Our Latest Stock Report on Cellebrite DI
Hedge Funds Weigh In On Cellebrite DI
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC increased its holdings in shares of Cellebrite DI by 93.3% during the third quarter. Elevation Wealth Partners LLC now owns 5,833 shares of the company’s stock worth $66,000 after buying an additional 2,816 shares in the last quarter. Tidal Investments LLC raised its stake in shares of Cellebrite DI by 12.5% in the second quarter. Tidal Investments LLC now owns 114,506 shares of the company’s stock valued at $1,672,000 after acquiring an additional 12,749 shares during the last quarter. Nine Ten Capital Management LLC raised its stake in shares of Cellebrite DI by 19.8% in the second quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock valued at $60,251,000 after acquiring an additional 682,933 shares during the last quarter. Light Street Capital Management LLC boosted its holdings in shares of Cellebrite DI by 104.8% in the 2nd quarter. Light Street Capital Management LLC now owns 1,312,755 shares of the company’s stock worth $19,166,000 after acquiring an additional 671,830 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Cellebrite DI by 93.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock worth $44,529,000 after acquiring an additional 1,475,579 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Cellebrite DI Company Profile
Cellebrite DI Ltd. (NASDAQ: CLBT) provides digital intelligence and digital forensics solutions that help organizations collect, preserve, analyze and manage data from mobile devices, computers, cloud environments and other digital sources. Its customers include law enforcement agencies, public safety organizations, government and intelligence bodies, military units, and corporate security and investigation teams.
The company’s offerings include tools for accessing and extracting digital evidence, case and evidence management, and investigative analytics.
See Also
- Five stocks we like better than Cellebrite DI
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
